Pharmaceutisch Weekblad

, Volume 11, Issue 3, pp 69–75 | Cite as


A new drug in the treatment of sleeping sickness
  • I. Van Bogaert
  • A. Haemers
Review Articles


Eflornithine (α-difluoromethylornithine; DFMO) is a recently developed drug against African trypanosomiasis (sleeping sickness). After a short description of trypanosomiasis and the current treatment, the mechanism of action of eflornithine is discussed, some clinical data is given and attention is paid to recently discovered analogues of eflornithine. Some examples of combination therapy with eflornithine and possible applications are mentioned.


Clinical trials Eflornithine Inhibition, enzyme-activated Ornithine decarboxylase Pharmacokinetics Trypanosomiasis Structure-activity relationship 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Brown JR. Human trypanosomiasis and their treatment. Pharm Int 1983;4:53–7.Google Scholar
  2. 2.
    UNDP, World Bank, WHO. Special programme for research and training in tropical diseases. Sixth programme report, 1983: chapter 5.Google Scholar
  3. 3.
    Henderson GB, Fairlamb AH, Cerami A. Trypanothione dependent peroxide metabolism inCrithidia fasciculata andTrypanosoma brucei. Mol Biochem Parasitol 1987; 24:39–45.PubMedGoogle Scholar
  4. 4.
    Fairlamb AH, Blackburn P, Ulrich P, Chait BT, Cerami A. Trypanothione: a novel bis (glutathionyl) spermidine cofactor for glutathione reductase in trypanosomatids. Science 1985;227:1485–7.PubMedGoogle Scholar
  5. 5.
    Fairlamb AH, Henderson GB, Bacchi CJ, Cerami A.In vivo effects of difluoromethylornithine on trypanothione and polyamine levels in bloodstream forms ofTrypanosoma brucei. Mol Biochem Parasitol 1987;24:185–91.PubMedGoogle Scholar
  6. 6.
    Henderson GB, Fairlamb AH, Ulrich P, Cerami A. Substrate specifity of the flavoprotein trypanothione disulfide reductase fromCrithidia fasciculata. Biochemistry 1987;26:3023–7.PubMedGoogle Scholar
  7. 7.
    Fairlamb AH, Henderson GB, Cerami A. The biosynthesis of trypanothione and N1-glutathionylspermidine inCrithidia fasciculata. Mol Biochem Parasitol 1986;21: 247–57.PubMedGoogle Scholar
  8. 8.
    Furet Y, Duong TH, Combescot C, Breteau M. Une molécule nouvelle en thérapeutique antiparasitaire: l'α-difluorométhylornithine. Pathol Biol 1987;35:398–404.PubMedGoogle Scholar
  9. 9.
    Bacchi CJ, Nathan HC, Clarkson AB, et al. Effects of the ornithine decarboxylase inhibitorsDl-α-difluoromethylornithine andα-monofluoromethyldehydroornithine methyl ester alone and in combination with suramin againstTrypanosoma brucei brucei central nervous system models. Am J Trop Med Hyg 1987;36:46–52.PubMedGoogle Scholar
  10. 10.
    Grillo MA. Metabolism and function of polyamines. Int J Biochem 1985;17:943–8.PubMedGoogle Scholar
  11. 11.
    Romyn JC, Verkoelen CF, Splinter TAW. Problems of pharmacokinetic studies onα-difluoromethylornithine in mice. Cancer Chemother Pharmacol 1987;19:30–4.PubMedGoogle Scholar
  12. 12.
    Bacchi CJ. Content, synthesis and function of polyamines in trypanosomatids: relationship to chemotherapy. J Protozool 1981;28:20–7.PubMedGoogle Scholar
  13. 13.
    McCann PP, Bacchi CJ, Clarkson AB. Inhibition of polyamine biosynthesis byα-difluoromethylornithine in African trypanosomes andPneumocystis carinii as a basis of chemotherapy: biochemical and clinical aspects. Am J Trop Med Hyg 1986;35:1153–6.PubMedGoogle Scholar
  14. 14.
    Kelland JG, Arnold LD, Palcic MM, Pickard MA, Vederas JC. Analogs of diaminopimelic acid as inhibitors of meso-diaminopimelate decarboxylase fromBacillus sphaericus and wheat germ. J Biol Chem 1986;261:13216–23.PubMedGoogle Scholar
  15. 15.
    Giffin BF, McCann PP, Bitonti AJ, Bacchi CJ. Polyamine depletion following exposure toDl-α-difluoromethylornithine bothin vivo andin vitro initiates morphological alterations and mitochondrial activation in a monomorphic strain ofTrypanosoma brucei brucei. J Protozool 1986;33:238–43.PubMedGoogle Scholar
  16. 16.
    Bitonti AJ, McCann PP, Sjoerdsma A. Necessity of antibody response in the treatment of African trypanosomiasis withα-difluoromethylornithine. Biochem Pharmacol 1986;35:331–4.PubMedGoogle Scholar
  17. 17.
    Taelman H, Schechter PJ, Marcelis L, et al. Difluoromethylornithine, an effective new treatment of Gambian trypanosomiasis. Am J Med 1987;82:607–13.PubMedGoogle Scholar
  18. 18.
    Bitonti AJ, Cross-Doersen DE, McCann PP. Effects ofα-difluoromethylornithine on protein synthesis and synthesis of the variant-specific glycoprotein (VSG) inTrypanosoma brucei brucei. Biochem J 1988;250:295–8.PubMedGoogle Scholar
  19. 19.
    Kierszenbaum F, Wirth JJ, McCann PP, Sjoerdsma A. Impairment of macrophage function by inhibitors of ornithine decarboxylase activity. Infect Immun 1987;55: 2461–4.PubMedGoogle Scholar
  20. 20.
    Bitonti AJ, Bacchi CJ, McCann PP, Sjoerdsma A. Uptake ofα-difluoromethylornithine byTrypanosoma brucei brucei. Biochem Pharmacol 1986;35:351–4.PubMedGoogle Scholar
  21. 21.
    Kierszenbaum F, Wirth JJ, McCann PP, Sjoerdsma A. Arginine decarboxylase inhibitors reduce the capacity ofTrypanosoma cruzi to infect and multiply in mammalian host cells. Proc Natl Acad Sci USA. 1987;84:4278–82.PubMedGoogle Scholar
  22. 22.
    Bitonti AJ, Casara PJ, McCann PP, Bey P. Catalytic irreversible inhibition of bacterial and plant arginine decarboxylase activities by novel substrate and product analogues. Biochem J 1987;242:69–74.PubMedGoogle Scholar
  23. 23.
    Pegg AE, McCann PP. Polyamine metabolism and function. Am J Physiol 1982;243:C212–22.PubMedGoogle Scholar
  24. 24.
    Haegele K, Alken RG, Grove J, Schechter PJ, Koch-Weser J. Kinetics ofα-difluoromethylornithine: an irreversible inhibitor of ornithine decarboxylase. Clin Pharm Ther 1981;30:210–7.Google Scholar
  25. 25.
    Sjoerdsma A, Schechter PJ. Chemotherapeutic implications of polyamine biosynthesis inhibition. Clin Pharmacol Ther 1984;35:287–98.PubMedGoogle Scholar
  26. 26.
    Van Nieuwenhove S, Schechter PJ, Declerq J, Bone G, Burke J, Sjoerdsma A. Treatment of gambiense sleeping sickness in the Sudan with oral DFMO, an inhibitor of ornithine decarboxylase, first field trial. Trans R Soc Trop Med Hyg 1985;79:692–8.PubMedGoogle Scholar
  27. 27.
    McCann PP, Bitonti AJ, Bacchi CJ, Clarkson AB Jr. Use of difluoromethylornithine (DFMO, eflornithine) for late stage African trypanosomiasis. Trans R Soc Trop Med Hyg 1987;81:701–2.Google Scholar
  28. 28.
    Petru AM, Azimi PH, Cummins SK, Sjoerdsma A. African sleeping sickness in the United States. Successful treatment with eflornithine. Am J Dis Child 1988;142:224–8.PubMedGoogle Scholar
  29. 29.
    Pepin J, Milord F, Guern C, Schechter PJ. Difluoromethylornithine for arsenoresistantTrypanosoma brucei gambiense sleeping sickness. Lancet 1987;2:1431–3.PubMedGoogle Scholar
  30. 30.
    Doua F, Boa FY, Schechter PJ, et al. Treatment of human late stage gambiense trypanosomiasis with alpha-difluoromethylornithine (eflornithine): efficacy and tolerance in 14 cases in Cote d'Ivoire. Am J Trop Med Hyg 1987;37:525–33.PubMedGoogle Scholar
  31. 31.
    Scalabrino G. Difluoromethylornithine, an effective new treatment of Gambian trypanosomiasis. Am J Med 1987;83:1012–3.PubMedGoogle Scholar
  32. 32.
    Mamont PS, Danzin C, Kolb M, Gerhart F, Bey P, Sjoerdsma A. Marked and prolonged inhibition of mammalian ornithinedecarboxylasein vivo by esters of (E)-2-(fluoromethyl)-dehydro-ornithine. Biochem Pharmacol 1986;35:159–65.PubMedGoogle Scholar
  33. 33.
    Bitonti AJ, Bacchi C, McCann PP, Sjoerdsma A. Catalytic irreversible inhibition ofTrypanosoma brucei brucei ornithinedecarboxylase by substrate and product analogs and their effects on murine trypanosomiasis. Biochem Pharmacol 1985;34:1773–7.PubMedGoogle Scholar
  34. 34.
    Bacchi CJ, Berens RZ, Nathan MC, et al. Synergism between 9-deazainosine andDl-α-difluoromethylornithine in treatment of experimental African trypanosomiasis. Antimicrob Agents Chemother 1987;31:1406–13.PubMedGoogle Scholar
  35. 35.
    Clarkson AB, Bienen EJ, Baceti CJ, McCann PP, Nathan HC, Hutner SH, Sjoerdsma A. New drug combination for experimental late-stage African trypanosomiasis:Dl-α-difluoromethylornithine with suramin. Am J Trop Med Hyg 1984;33:1073–7.PubMedGoogle Scholar
  36. 36.
    Clarkson AB, Bacchi CJ, Mellow GH, Nathan MC, McCann PP, Sjoerdsma A. Efficacy of combinations of difluoromethylornithine and bleomycin in a mouse model of central nervous system African trypanosomiasis. Proc Natl Acad Sci USA 1983;80:5729–33.PubMedGoogle Scholar
  37. 37.
    Sunkara PS, Rosenberger AL. Antimetastatic activity ofDl-α-difluoromethylornithine, an inhibition of polyamine biosynthesis, in mice. Cancer Res 1987;47:933–5.PubMedGoogle Scholar
  38. 38.
    Bitonti AJ, McCann PP, Sjoerdsma A.Plasmodium falciparum andPlasmodium berghei: effects of ornithine decarboxylase inhibitors on erythrocytic schizogony. Exp Parasitol 1987;64:237–43.PubMedGoogle Scholar
  39. 39.
    Pfaller MA, Gerarden T, Riley J. Growth inhibition of pathogenic yeast isolates byα-difluoromethylornithine: an inhibition of ornithine decarboxylase. Mycopathologia 1987;98:3–8.PubMedGoogle Scholar
  40. 40.
    Hughes WT. Treatment and prophylaxis forPneumocystis carinii pneumonia. Parasitol Today 1987;3:332–5.PubMedGoogle Scholar

Copyright information

© Bohn, Scheltema & Holkema 1989

Authors and Affiliations

  • I. Van Bogaert
    • 1
  • A. Haemers
    • 1
  1. 1.Department of Pharmaceutical SciencesUniversity of AntwerpAntwerpBelgium

Personalised recommendations